Drug Dosing Considerations in Alternative Hemodialysis

Advances in Chronic Kidney Disease

Volumn 14, Issue 3, 2007, Pages

  Decker, Brian S ^a   Mueller, Bruce A ^b   Sowinski, Kevin M ^a,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

computer simulation; Daily hemodialysis; drug dosing; mathematical modeling; pharmacodynamics; pharmacokinetics

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; DIGOXIN; GENTAMICIN; LEVOFLOXACIN; VANCOMYCIN;

ARTICLE; BLOOD FLOW VELOCITY; CHRONIC KIDNEY DISEASE; CONTINUOUS INFUSION; DIALYSATE; DISTRIBUTION VOLUME; DRUG CLEARANCE; EXTRACELLULAR SPACE; HEMODIALYSIS; HUMAN; LOADING DRUG DOSE; NOCTURNAL HEMODIALYSIS; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RISK BENEFIT ANALYSIS; SHORT DAILY HEMODIALYSIS; SOLUTE; STANDARDIZATION; SYSTEMATIC REVIEW; TECHNIQUE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTI-INFECTIVE AGENTS, URINARY; BLOOD UREA NITROGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GENTAMICINS; HEMODIALYSIS SOLUTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MONTE CARLO METHOD; OFLOXACIN; RENAL DIALYSIS; RISK FACTORS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 34250849661     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2007.03.004     Document Type: Article

References (31)

1. U.S. Renal Data System, USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States,National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2006
2. Henrich W.L. Principles and Practice of Dialysis (2004), Lippincott Williams & Wilkins, Philadelphia, PA
3. Matzke G.R., and Comstock T.J. Influence of renal function and dialysis on drug disposition. In: Burton M.E., Shaw L.M., Schentag J.J., and Evans W.E. (Eds). Applied Pharmacokinetics and Pharmacodynamics, Principles of Therapeutic Drug Monitoring (2006), Lippincott Williams & Wilkins, Philadelphia, PA 187-212
4. Atkinson A.J., and Susla G.M. Pharmacokinetics in patients receiving renal replacement therapy. In: Atkinson A.J., Abernethy D.R., Daniels C.E., Dedrick R.L., and Markey S.P. (Eds). Principles of Clinical Pharmacology (2007), Elsevier, New York, NY 59-72
5. Aronoff G.R., Berns J.S., and Brier M.E. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults. (ed 4) (1999), American College of Physicians, Philadelphia, PA
6. Suri R., Depner T.A., Blake P.G., et al. Adequacy of quotidian hemodialysis. Am J Kidney Dis 42 (2003) 42-48
7. Locatelli F., Buoncristiani U., Canaud B., et al. Dialysis dose and frequency. Nephrol Dial Transplant 20 (2005) 285-296
8. Lindsay R.M., Heidenheim A.P., Leitch R., et al. Short daily versus long nocturnal hemodialysis. ASAIO J 47 (2001) 449-455
9. Pierratos A. Daily hemodialysis: An update. Curr Opin Nephrol Hypertens 11 (2002) 165-171
10. Lacson E., and Diaz-Buxo J.A. Daily and nocturnal hemodialysis: How do they stack up?. Am J Kidney Dis 38 (2001) 225-239
11. Saner E., Nitsch D., Descoeudres C., et al. Outcome of home hemodialysis patients: A case-cohort study. Nephrol Dial Transplant 20 (2005) 604-610
12. Mucsi I., Hercz G., Uldall R., et al. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 53 (1998) 1399-1404
13. Messa P.M., Gropuzzo M., Boscutti C.G., et al. Behaviour of phosphate removal with different dialysis schedules. Nephrol Dial Transplant 13 suppl 6 (1998) 43-48
14. Clark W.R., Hamburger R.J., and Lysaught M.J. Effect of membrane composition and structure on solute removal and biocompatibility in hemodialysis. Kidney Int 56 (1999) 2005-2015
15. Manley H.J., Bailie G.R., McClaran M.L., et al. Gentamicin pharmacokinetics during slow daily home hemodialysis. Kidney Int 63 (2003) 1072-1078
16. Matsuo H., Hayashi J., Ono K., et al. Administration of aminoglycosides to hemodialysis patients immediately before dialysis: A new dosing modality. Antimicrob Agents Chemother 41 (1997) 2597-2601
17. Dang L., and Duffull S. Development of a semimechanistic model to describe the pharmacokinetics of gentamicin in patients receiving hemodialysis. J Clin Pharmacol 46 (2006) 662-673
18. Teigen M.M., Duffull S., Dang L., et al. Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis. J Clin Pharmacol 46 (2006) 1259-1267
19. Leypoldt J.K., Cheung A.K., Deeter R.B., et al. Kinetics of urea and beta-microglobulin during and after short hemodialysis treatments. Kidney Int 66 (2004) 1669-1676
20. Goldfarb-Rumyantzev A.S., Cheung A.K., and Leypoldt J.K. Computer simulation of small-solute and middle-molecule removal during short daily and long thrice-weekly hemodialysis. Am J Kidney Dis 40 (2002) 1211-1218
21. Clark W.R., Leypoldt J.K., Henderson L.W., et al. Quantifying the effect of changes in the hemodialysis prescription on effective solute removal with a mathematical model. J Am Soc Nephrol 10 (1999) 601-609
22. Twardowski Z.J. Treatment time and ultrafiltration rate are more important in dialysis prescription than small molecule clearance. Blood Purif 25 (2007) 90-98
23. Mueller B.A., Pasko D.A., and Sowinski K.M. Higher renal replacement therapy dose delivery influences on drug therapy. Artif Organs 27 (2003) 808-814
24. Sowinski K.M., Magner S., Lucksiri A., et al. Solute removal characteristics of the CAHP-210 hemodialyzer: In vitro and in vivo performance. Pharmacotherapy 21 (2001) 1288-1289
25. Sowinski K.M., Lucksiri A., Kays M.B., et al. Levofloxacin pharmacokinetics in end-stage renal disease and removal by the CAHP-210 hemodialyzer. Am J Kidney Dis 42 (2003) 342-349
26. Lucksiri A., Scott M.K., Mueller B.A., et al. CAHP-210 dialyzer influence on intradialytic vancomycin bioavailability. Nephrol Dial Trans 17 (2002) 1649-1654
27. Sowinski K.M., Mueller B.A., Grabe D.W., et al. Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers. Am J Kidney Dis 37 (2001) 766-776
28. Spivey J.M., Blum R.A., and Nix D.E. Mathematic modeling of drug disposition and postdialysis rebound in patients requiring hemodialysis. Pharmacotherapy 12 (1992) 201-206
29. D'Argenio D.Z., and Schumitzky A. ADAPT II Release 4, User's Guide (1997), Biomedical Simulations Resource, University of Southern California, Los Angeles, CA
30. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 26 (1998) 1-10
31. Pai A.B., and Pai M.P. Optimizing antimicrobial therapy for gram-positive bloodstream infections in patients on hemodialysis. Adv Chronic Kidney Dis 13 (2006) 259-270